RenovoRx, Inc.
RNXT•NASDAQ•Healthcare•Biotechnology

About RenovoRx

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOShaun Bagai
Founded2012
IPO DateAugust 26, 2021
Employees10
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websiterenovorx.com
Phone650 284 4433
Address
2570 West El Camino Real, Suite 320 Mountain View, California 94040 United States

Corporate Identifiers

CIK0001574094
CUSIP75989R107
ISINUS75989R1077
EIN27-1448452
SIC2834

Leadership Team & Key Executives

Shaun R. Bagai
Chief Executive Officer, Secretary and Director
Dr. Ramtin Agah M.D.
Founder, Chairman of Board and Chief Medical Officer
Leesa Gentry
Chief Clinical Officer
Robert Strasser
Vice President of Operations and Research & Development
Ronald B. Kocak CPA, CGMA
Vice President, Controller and Principal Accounting Officer
Ryan Witt
Senior Vice President and Head of Corporate Strategy and Partnerships